ArticleThe Kaohsiung journal of medical sciences2025
Circulating let-7 Predicts Hepatic Fibrogenesis of 12-Month Post-Nucleos(t)ide Analog Treatment in Patients With Hepatitis B Virus.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Chronic hepatitis B virus (HBV) infection is associated with potential complications of liver cirrhosis and hepatocellular carcinoma. To date, there are no effective and noninvasive clinical markers that can predict the risk of liver fibrosis early and accurately in chronic hepatitis B (CHB) patients treated with nucleos(t)ide analogs (NAs). This study aimed to investigate the association of circulating let-7b/c/g levels with the severity of hepatic fibrosis with a FIB-4 index of 1.5-2.9 in CHB patients. We conducted a retrospective longitudinal study in patients with CHB after 6 months of NAs therapy to investigate whether serum let-7b/c/g levels can be monitored as an early biomarker for liver fibrogenesis based on multivariate logistic regression analyses. We also used the hepatic stellate cell line LX-2 treated with transforming growth factor-β (TGF-β) to evaluate the suppression effect of let-7b/c/g on hepatic fibrogenesis. The study showed that circulating let-7b/c/g could predict 12 months of antiviral treatment for HBV-related significant fibrosis (FIB-4 index ≥ 2.9) at baseline and was significantly negatively correlated with the FIB-4 score. Moreover, let-7b/c/g could directly target the TGF-βR1-3' untranslated region (3' UTR) and inhibit TGF-β induced p-SMAD2 phosphorylation to reduce α-smooth muscle actin levels, a fibrogenesis marker in LX-2 cells. These results confirm that let-7b/c/g could be a biomarker for monitoring HBV-induced fibrogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.